Delivery Order SPE2DB20D7061-SPE2DB25FSMR5

Award Date 3/27/25
Potential Completion Date 4/17/25
Potential Value $1.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,314.17 firm fixed-price contract is for the delivery of HYPERRAB 300 UNIT/ML VIAL 5ML, a medical product. The award is associated with a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for providing...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,719.46 firm-fixed-price delivery order is for HYPERRAB 300UNIT/ML 1S medical supplies. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to...
This federal contract award, valued at $7,163.24, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a medical product, with a completion date of May 1, 2025. The contract is a firm fixed-price, non-set-aside award, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical distribution company Amerisourcebergen Corporation. The $9,391.75 Delivery Order is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a pharmaceutical product. The contract is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. This...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order valued at $3,581.62 for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a medical product. The contract has a ceiling value of $3,581.62 and a period of performance through March 4, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,490.29 firm fixed-price delivery order is for the supply of HYPERRAB 300 UNIT/ML VIAL 3ML medical products. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products...
This federal contract award, valued at $21,489.60, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HYPERRAB 300 UNIT/ML VIAL 5ML, a medical product, with a completion date of February 25, 2025. The contract is a Delivery Order on a Firm Fixed Price basis and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,716.30 firm fixed-price delivery order is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a medical product. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award, with a total ceiling value of $7,513.40, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office division. The contract is for the delivery of HYPERRAB 300 UNIT/ML VIAL 5ML, a critical pharmaceutical product. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for the supply...
This federal contract award, valued at $1,790.80, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HYPERRAB 300 UNIT/ML VIAL 5ML, a pharmaceutical product, and does not have a set-aside designation. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
  • SPE2DB20D7061
    Indefinite Delivery Contract
  • SPE2DB20D7061-SPE2DB25FSMR5
    Delivery Order

This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,732.55, is a delivery order for 4,568,001,174 units of HYPERRAB 300 UNIT/ML VIALML. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC covers a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition. This award demonstrates AmerisourceBergen's role as a key vendor for federal healthcare programs, particularly within the military and veterans' healthcare systems.

Generated 6/26/25, 9:50 AM